- Home
- BTAI vs CEAD Comparison
BTAI vs CEAD Comparison
Compare BTAI & CEAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- CEAD
- Stock Information
- Founded
- BTAI 2017
- CEAD 2009
- Country
- BTAI United States
- CEAD United States
- Employees
- BTAI N/A
- CEAD N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- CEAD Industrial Machinery/Components
- Sector
- BTAI Health Care
- CEAD Industrials
- Exchange
- BTAI Nasdaq
- CEAD Nasdaq
- Market Cap
- BTAI 6.6M
- CEAD 6.4M
- IPO Year
- BTAI 2018
- CEAD N/A
- Fundamental
- Price
- BTAI $2.13
- CEAD $11.65
- Analyst Decision
- BTAI Buy
- CEAD
- Analyst Count
- BTAI 4
- CEAD 0
- Target Price
- BTAI $37.00
- CEAD N/A
- AVG Volume (30 Days)
- BTAI 279.4K
- CEAD 17.5K
- Earning Date
- BTAI 03-11-2025
- CEAD 03-27-2025
- Dividend Yield
- BTAI N/A
- CEAD N/A
- EPS Growth
- BTAI N/A
- CEAD N/A
- EPS
- BTAI N/A
- CEAD N/A
- Revenue
- BTAI $2,276,000.00
- CEAD $2,637,116.00
- Revenue This Year
- BTAI $105.36
- CEAD N/A
- Revenue Next Year
- BTAI $46.93
- CEAD N/A
- P/E Ratio
- BTAI N/A
- CEAD N/A
- Revenue Growth
- BTAI 83.25
- CEAD N/A
- 52 Week Low
- BTAI $2.10
- CEAD $5.60
- 52 Week High
- BTAI $56.00
- CEAD $12.26
- Technical
- Relative Strength Index (RSI)
- BTAI 28.68
- CEAD 74.27
- Support Level
- BTAI $2.18
- CEAD $10.33
- Resistance Level
- BTAI $2.60
- CEAD $11.15
- Average True Range (ATR)
- BTAI 0.44
- CEAD 0.68
- MACD
- BTAI -0.08
- CEAD 0.44
- Stochastic Oscillator
- BTAI 0.94
- CEAD 87.90
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About CEAD CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.